Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CFT7455 |
Synonyms | |
Therapy Description |
CFT7455 interacts with CRL4-CRBN E3 ligase and degrades IKZF1/3, potentially inhibiting proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB007). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CFT7455 | CFT-7455|CFT 7455 | CFT7455 interacts with CRL4-CRBN E3 ligase and degrades IKZF1/3, potentially inhibiting proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB007). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04756726 | Phase Ib/II | CFT7455 CFT7455 + Dexamethasone | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |